Quote | Addex Therapeutics Ltd (NASDAQ:ADXN)
Last: | $18.74 |
---|---|
Change Percent: | 3.01% |
Open: | $18.7 |
Close: | $18.74 |
High: | $18.74 |
Low: | $17.5 |
Volume: | 12,934 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | Addex Therapeutics Ltd (NASDAQ:ADXN)
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April ...
2024-04-18 13:46:03 ET Addex Therapeutics Ltd (ADXN) Q4 2023 Earnings Conference Call April 18, 2024, 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Joanne ...
Message Board Posts | Addex Therapeutics Ltd (NASDAQ:ADXN)
Subject | By | Source | When |
---|---|---|---|
Watch for this to have its days, low | harry crumb | investorshub | 05/11/2023 1:00:53 AM |
The float is already traded... big boom ahead imo | Klinsmann | investorshub | 05/10/2023 10:46:10 AM |
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Studys | subslover | investorshub | 05/10/2023 9:59:36 AM |
Price trading up | glenn1919 | investorshub | 05/09/2023 3:35:34 AM |
$ADXN MomentumIts gaining | willlbone | investorshub | 05/07/2023 8:43:30 AM |
News, Short Squeeze, Breakout and More Instantly...
Addex Therapeutics Ltd Company Name:
ADXN Stock Symbol:
NASDAQ Market:
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April ...
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing ...
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial res...